The FDA has approved one specific incretin-based medication for sleep apnea: Zepbound, which contains tirzepatide. The indication is for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, together with a reduced-calorie diet and increased physical activity 1.
Tirzepatide is not simply a GLP-1 receptor agonist. It activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Calling it a "GLP-1 drug" is common shorthand, but the distinction matters because the OSA approval and randomized trial evidence belong to tirzepatide and the Zepbound product. They do not establish an OSA benefit for semaglutide, liraglutide, Ozempic, Wegovy, or every medicine in the broader GLP-1 category 1 2.
Zepbound is not approved by this indication for central sleep apnea, mild OSA, children, adults without obesity, or as a weight-independent treatment for airway collapse. It also should not be used to decide on your own that positive airway pressure (PAP) or another OSA treatment is no longer needed 1.
What exactly did the FDA approve?
The FDA approved Zepbound for this OSA indication in December 2024. The label specifies all of the following 1 2:
- The condition is obstructive sleep apnea, not central sleep apnea.
- OSA must be moderate to severe, rather than mild.
- The patient is an adult with obesity.
- Treatment is used with a reduced-calorie diet and increased physical activity.
Those label boundaries are different from saying that anyone who snores, has fatigue, or receives a high risk score should start the drug. OSA diagnosis and severity require an appropriate sleep evaluation and objective sleep testing. A prescriber also has to decide whether Zepbound fits the person's medical history, other medicines, treatment goals, and risks 3.
The same active ingredient can be sold under different product labels, and different medicines can share part of a drug mechanism. Neither fact transfers an FDA indication. The OSA indication is specific to Zepbound. It is not a class approval for GLP-1 receptor agonists 1 2.
What SURMOUNT-OSA studied
SURMOUNT-OSA consisted of two manufacturer-funded, 52-week, phase 3 randomized trials. Both compared the maximum tolerated dose of tirzepatide, 10 or 15 milligrams once weekly, with placebo. All participants received reduced-calorie diet guidance and physical activity counseling 4.
The trials enrolled 469 adults with obesity and moderate-to-severe OSA. Their average body mass index was about 39, their average apnea-hypopnea index (AHI) was about 50 events per hour, and most participants were men. People with type 2 diabetes were excluded 4 1.
The two trials answered different treatment-context questions:
- Study 1, without PAP: This trial included 234 adults who were unable or unwilling to use PAP.
- Study 2, established PAP users: This trial included 235 adults who were using PAP and intended to continue it. PAP was suspended for seven days before the week 52 sleep-study assessment so researchers could measure OSA without PAP masking the drug's effect. The study did not determine when it would be safe or appropriate for an established PAP user to stop treatment 1.
Study 2 was not a head-to-head test of tirzepatide against PAP. It also was not a test showing that PAP plus tirzepatide during the measured night was superior to either treatment alone. The week 52 AHI was measured after the PAP washout 4.
The main results at 52 weeks
The table below uses the treatment-regimen estimand, the trial's main statistical perspective. It included randomized participants who received at least one dose, whether or not they later stopped treatment, and used multiple imputation for missing week 52 data. The trial also reported an efficacy estimand that asked what the average effect might be if participants remained on assigned treatment for the planned duration. Those estimates were somewhat larger, so the two sets of numbers should not be mixed 4.
| Outcome at week 52 | Study 1: unable or unwilling to use PAP | Study 2: established PAP users |
|---|---|---|
| AHI change from baseline | Tirzepatide: -25.3 events/hour; placebo: -5.3 | Tirzepatide: -29.3 events/hour; placebo: -5.5 |
| Absolute AHI treatment difference | -20.0 events/hour versus placebo (95% CI -25.8 to -14.2) | -23.8 events/hour versus placebo (95% CI -29.6 to -17.9) |
| At least 50% lower AHI | Tirzepatide: 61.2%; placebo: 19.0% | Tirzepatide: 72.4%; placebo: 23.3% |
| Trial composite of remission or mild OSA without elevated sleepiness | Tirzepatide: 42.2%; placebo: 15.9% | Tirzepatide: 50.2%; placebo: 14.3% |
| Sleep apnea-specific hypoxic burden change | Tirzepatide: -95.2 percentage-minutes/hour; placebo: -25.1; treatment difference: -70.1 | Tirzepatide: -103.0 percentage-minutes/hour; placebo: -41.7; treatment difference: -61.3 |
| Body-weight change | Tirzepatide: -17.7%; placebo: -1.6%; treatment difference: -16.1 percentage points | Tirzepatide: -19.6%; placebo: -2.3%; treatment difference: -17.3 percentage points |
These are group averages, not a forecast for one person. Hypoxic burden combines the frequency, depth, and duration of oxygen drops tied to respiratory events. A lower value suggests less exposure to event-related low oxygen, but it does not replace the rest of the sleep-study report or prove that long-term cardiovascular events will be prevented 4.
The trial's "remission or mild non-symptomatic OSA" result also needs a precise definition. A participant met the composite if the AHI was below 5, or if the AHI was 5 to 14 with an Epworth Sleepiness Scale score of 10 or less. It does not mean everyone in that group had an AHI below 5, felt no symptoms, or was permanently cured. About half of tirzepatide-treated participants did not meet the composite at week 52 4.
How much of the effect came from weight loss?
The most established explanation is weight reduction. Reducing fat around the upper airway and other obesity-related mechanical loads can make the airway less prone to collapse. The FDA states that the observed improvement in AHI was likely related to body-weight reduction with Zepbound 2.
The trials also found changes in high-sensitivity C-reactive protein, blood pressure, and other outcomes. These findings do not prove that tirzepatide treats OSA through an independent anti-inflammatory, glucose, hormone, or circadian pathway. Participants with type 2 diabetes were excluded, and the trials were not designed to isolate an OSA effect that occurred independently of weight change 4.
It is therefore more accurate to say that tirzepatide improved OSA while producing substantial weight loss in the studied population. It is not established as a weight-independent airway drug.
Why improvement does not mean you can stop PAP
PAP holds the airway open while it is being worn. Tirzepatide works gradually and does not provide that immediate mechanical support. An oral appliance, positional treatment, or surgical plan also has its own mechanism and follow-up requirements.
Keep using PAP, an oral appliance, positional therapy, or another prescribed OSA treatment unless the sleep clinician responsible for the plan changes it. The Zepbound trials did not establish a timetable or rule for stopping PAP, and the current label says the PAP-user study did not evaluate when discontinuation would be appropriate 1.
Feeling less sleepy, snoring less, losing weight, or seeing better numbers on a watch or ring cannot by itself establish that OSA has resolved. Symptoms may improve while clinically important breathing events or oxygen drops remain. Consumer sleep technology is not a substitute for clinician-directed polysomnography or a suitable home sleep apnea test 5.
The American Academy of Sleep Medicine says follow-up polysomnography or home sleep apnea testing may be used after clinically significant weight gain or loss, and recommends follow-up testing to assess response to non-PAP treatments. The test and timing depend on the person and whether the result would change treatment 6.
A sensible sequence is:
- Continue the existing OSA treatment.
- Track weight change, side effects, symptoms, and PAP or appliance issues with the treating clinicians.
- Ask whether repeat objective testing is appropriate after a substantial, stable change.
- Change PAP settings, stop PAP, or alter another treatment only through the clinical plan.
Dosing context, not a self-prescribing schedule
The current U.S. Zepbound label starts treatment at 2.5 milligrams once weekly for four weeks. It then moves to 5 milligrams, with any further increases made in 2.5-milligram steps after at least four weeks at the current dose. The recommended maintenance dosage for OSA is 10 or 15 milligrams once weekly, and 2.5 milligrams is an initiation dose rather than a maintenance dose. The maximum recommended dosage is 15 milligrams once weekly 1.
This information explains how the labeled titration relates to the trial. It is not a personal schedule. A prescriber determines whether treatment is suitable, how tolerability affects escalation, and when adverse effects or another medical issue require a pause, change, or stop. The label also advises against combining Zepbound with another tirzepatide-containing product or any GLP-1 receptor agonist 1.
Main risks and contraindications
The safety information for Zepbound should come from its current label, not from a warning attached to another molecule.
Boxed thyroid warning and contraindications
Tirzepatide caused thyroid C-cell tumors in rats. It is unknown whether it causes these tumors, including medullary thyroid carcinoma, in humans. Zepbound is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2. It is also contraindicated after a known serious hypersensitivity reaction to tirzepatide or a Zepbound ingredient 1.
A new neck lump, persistent hoarseness, trouble swallowing, or trouble breathing warrants prompt medical assessment. Sudden swelling of the face, lips, tongue, or throat, trouble breathing, faintness, or another possible severe allergic reaction requires emergency care 1.
Gastrointestinal effects, dehydration, and kidney injury
Nausea, vomiting, diarrhea, constipation, abdominal discomfort, and reflux can occur, and gastrointestinal reactions are sometimes severe. Zepbound is not recommended for people with severe gastroparesis. Vomiting or diarrhea can cause dehydration, which has been linked to acute kidney injury, particularly around treatment initiation and dose escalation 1.
Contact the prescriber promptly for persistent vomiting or diarrhea. Seek urgent care if you cannot keep fluids down, are fainting, become confused, produce very little urine, or have other signs of severe dehydration.
Gallbladder disease and pancreatitis
Acute gallbladder disease has occurred with Zepbound. Gallstones are not listed as an automatic contraindication, but new upper abdominal pain, fever, yellowing of the skin or eyes, or concerning digestive symptoms need clinical assessment 1.
Persistent or severe abdominal pain, especially if it radiates to the back and occurs with or without vomiting, can be a sign of acute pancreatitis. Stop using Zepbound and seek urgent medical assessment if pancreatitis is suspected 1.
Low blood glucose with certain diabetes medicines
Zepbound lowers blood glucose. The risk of hypoglycemia is higher when it is combined with insulin or an insulin secretagogue such as a sulfonylurea. A clinician may need to adjust those medicines and provide a monitoring and treatment plan 1.
Follow the established hypoglycemia plan. Confusion, loss of consciousness, or a seizure is an emergency.
Delayed stomach emptying, procedures, and oral medicines
Tirzepatide delays gastric emptying and can affect absorption of oral medicines. The label calls for caution with oral drugs that need a threshold concentration or have a narrow therapeutic index 1.
Rare aspiration events have been reported during general anesthesia or deep sedation even when patients reported following fasting instructions. Tell the surgeon, anesthesiologist, procedural team, and prescriber that you use Zepbound before any planned procedure. The label says evidence is insufficient to set one universal stopping or fasting strategy, so do not invent one without the procedure team 1.
Pregnancy and oral contraception
Zepbound may cause fetal harm and should be discontinued when pregnancy is recognized. Contact the prescriber promptly rather than continuing it for weight loss during pregnancy 1.
Because delayed gastric emptying may reduce the effectiveness of oral hormonal contraceptives, the label advises switching to a non-oral contraceptive method or adding a barrier method for four weeks after starting Zepbound and for four weeks after each dose increase. Non-oral hormonal contraceptives are not expected to be affected in the same way 1.
What to discuss with the sleep clinician and prescriber
Bring the following information to a shared treatment discussion:
- your diagnostic report, including OSA type, AHI or respiratory event index, oxygen findings, and severity
- your current PAP, oral-appliance, positional, or surgical treatment and how consistently it is used
- current symptoms, especially unintended sleep episodes or drowsy driving
- weight history and the role obesity is thought to play in your OSA
- diabetes medicines, oral medicines with narrow dosing margins, and all other prescriptions and supplements
- personal or family history of medullary thyroid carcinoma or MEN 2
- prior severe allergic reactions, severe gastroparesis, pancreatitis, gallbladder disease, kidney problems, or recurrent dehydration
- pregnancy plans, current pregnancy, and contraceptive method
- any planned surgery, endoscopy, or procedure involving general anesthesia or deep sedation
- what improvement would count as success and when objective sleep retesting would change the plan
If sleepiness makes driving or hazardous work unsafe, stop the activity and arrange help. Medication-supported weight loss takes time, and it should not be treated as immediate protection from OSA-related impairment.
Frequently asked questions
Is Zepbound a GLP-1 drug?
It is commonly grouped with GLP-1 medicines, but tirzepatide is a dual GIP and GLP-1 receptor agonist. That dual action and the product-specific evidence are why "all GLP-1 drugs treat sleep apnea" is not a valid conclusion 1.
Are Ozempic or Wegovy approved for sleep apnea?
The FDA OSA approval discussed here is for Zepbound in adults with obesity and moderate-to-severe OSA. It is not a class approval for semaglutide products such as Ozempic or Wegovy, liraglutide, or other GLP-1 receptor agonists 2.
Does Zepbound cure obstructive sleep apnea?
Tirzepatide substantially reduced AHI for many trial participants, but only 42.2% in the non-PAP trial and 50.2% in the PAP-user trial met the study's combined remission or mild-range, low-sleepiness endpoint at week 52. The trials did not establish durable cure or show what happens to OSA after the medication is stopped 4.
Can Zepbound treat central sleep apnea?
The approved indication and SURMOUNT-OSA evidence are for obstructive sleep apnea. They do not establish treatment for central sleep apnea 1.
When should sleep apnea be retested after weight loss?
There is no single date that fits everyone. Follow-up testing may be appropriate after clinically significant weight change or when the result would alter treatment. The sleep clinician should choose the timing and whether polysomnography or a home sleep apnea test is suitable 6.
